Quarterly 13F snapshot: US-listed longs only, no performance figures — 13F data cannot support them.
Reported portfolio value by quarter (16 quarters reported)
$779M in Q4 2021 → $65.6M now. Hover for any quarter.
As reported for the quarter ended September 30, 2025. Activity is the change in share count since the prior quarter's filing.
| Holding | % of portfolio | Activity | Shares | Value |
|---|---|---|---|---|
| Recursion Pharmaceuticals, Inc. | 100.0% | Unchanged | 13,434,171 | $65.6M |
What changed each quarter, from the filings' own share counts. Largest moves first; most recent 8 quarters.
quarter ended September 30, 2025 · filed November 04, 2025
No position changes this quarter.
quarter ended June 30, 2025 · filed August 13, 2025
No position changes this quarter.
quarter ended March 31, 2025 · filed April 28, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Recursion Pharmaceuticals, Inc. | Added | +1,528,503 | +$8.09M | 100.0% |
quarter ended December 31, 2024 · filed January 23, 2025
No position changes this quarter.
quarter ended September 30, 2024 · filed October 15, 2024
No position changes this quarter.
quarter ended June 30, 2024 · filed July 08, 2024
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Recursion Pharmaceuticals, Inc. | Added | +1,500,000 | +$11.3M | 100.0% |
quarter ended March 31, 2024 · filed April 15, 2024
No position changes this quarter.
quarter ended December 31, 2023 · filed February 02, 2024
No position changes this quarter.
Loading...
